TY  - JOUR
AU  - Huber, Hanna
AU  - Arranz, Javier
AU  - Arslan, Burak
AU  - Leuzy, Antoine
AU  - Kittel, Oscar
AU  - di Molfetta, Guglielmo
AU  - Benejam, Bessy
AU  - Videla, Laura
AU  - Barroeta, Isabel
AU  - Soriano, Laura Del Hoyo
AU  - Maure-Blesa, Lucía
AU  - Rodríguez-Baz, Íñigo
AU  - Arriola Infante, José Enrique
AU  - Illán-Gala, Ignacio
AU  - Bejanin, Alexandre
AU  - Montoliu-Gaya, Laia
AU  - Lleó, Alberto
AU  - Carmona-Iragui, María
AU  - Alcolea, Daniel
AU  - Blennow, Kaj
AU  - Zetterberg, Henrik
AU  - Fortea, Juan
AU  - Ashton, Nicholas J
TI  - Plasma p-tau217 as a biomarker of Alzheimer's disease pathology in individuals with Down syndrome.
JO  - Nature Communications
VL  - 16
IS  - 1
SN  - 2041-1723
CY  - [London]
PB  - Springer Nature
M1  - DZNE-2025-01255
SP  - 9900
PY  - 2025
AB  - Diagnosing Alzheimer's disease (AD) in adults with Down syndrome (DS), a population with a high genetically determined risk of AD, remains challenging. In this large observational study including n = 2329 samples from the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI) and euploid controls from the Sant Pau Initiative on Neurodegeneration (SPIN) with and without symptomatic AD, we investigate if the strong diagnostic performance of plasma p-tau217 observed in sporadic AD extends to the DS population. Plasma p-tau217 discriminated cognitively stable individuals with DS from those with AD dementia with an AUC of 0.96 (95
LB  - PUB:(DE-HGF)16
C6  - pmid:41213934
DO  - DOI:10.1038/s41467-025-65882-x
UR  - https://pub.dzne.de/record/281913
ER  -